A BILL 
To require the Secretary of Health and Human Services 
to establish a demonstration project to increase access 
to biosimilar biological products under the Medicare pro-
gram. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Increasing Access to 
4
Biosimilars Act of 2021’’. 
5
19:25 Jun 18, 2021
H2869
2 
•HR 2869 IH
SEC. 2. DEMONSTRATION PROJECT TO INCREASE ACCESS 
1
TO 
BIOSIMILAR 
BIOLOGICAL 
PRODUCTS 
2
UNDER THE MEDICARE PROGRAM. 
3
(a) ESTABLISHMENT.—Beginning not later than 1 
4
year after the date of the enactment of this Act, the Sec-
5
retary of Health and Human Services shall establish and 
6
implement a 3-year nationwide demonstration project 
7
under part B of title XVIII of the Social Security Act to 
8
evaluate the benefits of providing a shared savings pay-
9
ment for biosimilar biological products furnished under 
10
such part. 
11
(b) PARTICIPATION.— 
12
(1) IN
GENERAL.—Participation under the 
13
demonstration project shall be voluntary, and a par-
14
ticipating provider may terminate participation at 
15
any time and the Secretary may terminate the par-
16
ticipation of such a provider at any time. 
17
(2) APPLICATION AND SELECTION.—To partici-
18
pate under the demonstration project, an eligible 
19
provider shall submit to the Secretary an application 
20
in such form and manner and containing such infor-
21
mation as specified by the Secretary. Each eligible 
22
provider who submits such an application shall be 
23
selected by the Secretary for participation under the 
24
demonstration project. 
25
19:25 Jun 18, 2021
H2869
3 
•HR 2869 IH
(3) CLARIFICATION.—Participation under the 
1
demonstration project shall not preclude eligible pro-
2
viders from also participating in any model author-
3
ized under section 1115A of the Social Security Act 
4
(42 U.S.C. 1315a), including the Oncology Care 
5
Model and Oncology Care First Model, or impact eli-
6
gible providers metrics or expenditures within other 
7
models authorized under such section. 
8
(c) COVERAGE.—Except as otherwise provided in this 
9
section, payment may be made under the demonstration 
10
project for a biosimlar biological product only if such prod-
11
uct is covered under part B of title XVIII of the Social 
12
Security Act and such payment shall be made in the same 
13
manner as payment is provided for such a product under 
14
such part. 
15
(d) ADDITIONAL PAYMENT.— 
16
(1) IN
GENERAL.—Under the demonstration 
17
project, subject to paragraph (3), in addition to the 
18
payment that would otherwise be made under part 
19
B of title XVIII of the Social Security Act for a bio-
20
similar biological product furnished or dispensed by 
21
a participating provider to a Medicare beneficiary, 
22
there shall be made an additional payment, in an 
23
amount determined by the Secretary, that is based 
24
on the difference, if any, (or portion of such dif-
25
19:25 Jun 18, 2021
H2869
4 
•HR 2869 IH
ference) between the costs to the provider in fur-
1
nishing the biosimilar biological product and the 
2
costs to the provider if the provider had furnished 
3
the reference biological product. 
4
(2) NO
INCREASE
TO
MEDICARE
COINSUR-
5
ANCE.—The additional payment described under 
6
paragraph (1) shall not increase a Medicare bene-
7
ficiary’s cost-sharing liability, as described in section 
8
1833 of the Social Security Act (42 U.S.C. 1395l). 
9
(3) EXCEPTION.—An eligible provider may only 
10
receive the additional payment described in para-
11
graph (1), with respect to a biosimilar biological 
12
product, if the payment amount under section 
13
1847A of the Social Security Act (42 U.S.C. 
14
1395w–3a) for such product is less than the pay-
15
ment amount under part B of title XVIII of such 
16
Act for the reference biological product. 
17
(e) WAIVER AUTHORITY.—The Secretary may waive 
18
such requirements of title XVIII of the Social Security Act 
19
as may be necessary to carry out the demonstration 
20
project, except the Secretary may not increase the cost- 
21
sharing that would otherwise, without application of this 
22
section, be applied to an individual under section 1833 of 
23
the Social Security Act (42 U.S.C. 1395l). 
24
(f) REPORTS.— 
25
19:25 Jun 18, 2021
H2869
5 
•HR 2869 IH
(1) INTERIM EVALUATION AND REPORT.—Not 
1
later than 3 years after the date of enactment of 
2
this Act, the Secretary shall submit to Congress a 
3
report that contains an analysis of the appropriate-
4
ness of expanding or extending the demonstration 
5
project and, to the extent such analysis determines 
6
such an expansion or extension appropriate, rec-
7
ommendations for such expansion or extension, re-
8
spectively. 
9
(2) FINAL
EVALUATION
AND
REPORT.—Not 
10
later than one year after the date of completion of 
11
the demonstration project, the Secretary shall sub-
12
mit to Congress a report that contains a final anal-
13
ysis of the project and recommendations described in 
14
paragraph (1). 
15
(g) DEFINITIONS.—In this section: 
16
(1) DEMONSTRATION
PROJECT.—The term 
17
‘‘demonstration project’’ means the demonstration 
18
project conducted under this Act. 
19
(2) BIOSIMILAR
BIOLOGICAL
PRODUCT.—The 
20
term ‘‘biosimilar biological product’’ means a biologi-
21
cal product approved under an abbreviated applica-
22
tion for a license of a biological product that relies 
23
in part on data or information in an application for 
24
19:25 Jun 18, 2021
H2869
6 
•HR 2869 IH
another biological product licensed under section 351 
1
of the Public Health Service Act (42 U.S.C. 262). 
2
(3) ELIGIBLE PROVIDER.—The term ‘‘eligible 
3
provider’’ means a provider of services or supplier 
4
that is eligible to receive payment under part B of 
5
title XVIII of the Social Security Act for furnishing 
6
or dispensing biosimilar biological products. 
7
(4) 
MEDICARE
BENEFICIARY.—The 
term 
8
‘‘Medicare beneficiary’’ means an individual who is 
9
enrolled for benefits under part B of title XVIII of 
10
the Social Security Act. 
11
(5) 
PARTICIPATING
PROVIDER.—The 
term 
12
‘‘participating provider’’ means an eligible provider 
13
that has been selected for participation under the 
14
project under subsection (b)(2) and with respect to 
15
whom such participation has not been terminated. 
16
(6) REFERENCE
BIOLOGICAL
PRODUCT.—The 
17
term ‘‘reference biological product’’ means the bio-
18
logical product licensed under section 351 of the 
19
Public Health Service Act (42 U.S.C. 262) that is 
20
referred to in the application described in paragraph 
21
(2) of the biosimilar biological product. 
22
Æ 
19:25 Jun 18, 2021
H2869
